Compare AAUC & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AAUC | AGIO |
|---|---|---|
| Founded | N/A | 2007 |
| Country | Canada | United States |
| Employees | 2095 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.3B |
| IPO Year | N/A | 2013 |
| Metric | AAUC | AGIO |
|---|---|---|
| Price | $20.97 | $36.34 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $38.88 |
| AVG Volume (30 Days) | 218.6K | ★ 1.1M |
| Earning Date | 05-19-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,011,000.00 |
| Revenue This Year | $94.92 | $76.75 |
| Revenue Next Year | $27.93 | $170.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.40 | $22.24 |
| 52 Week High | $32.20 | $46.00 |
| Indicator | AAUC | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 34.94 | 47.03 |
| Support Level | $20.58 | $26.71 |
| Resistance Level | $25.01 | $44.51 |
| Average True Range (ATR) | 0.86 | 1.85 |
| MACD | -0.01 | -0.87 |
| Stochastic Oscillator | 21.32 | 13.39 |
Allied Gold Corp is a company focused on gold mining activities in Africa. Allied has three mines and several development and exploration projects in Africa, where it has operating experience. Operations are located in Cote d'Ivoire, Mali, and Ethiopia. The company expands and optimizes initiatives at existing operating mines, develops new mines, advances its exploration properties, and targets other consolidation opportunities, with a focus on Africa.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.